Beth Israel Lahey Health President and CEO Kevin Tabb, MD, plans to step down in one year after more than 14 years leading the system and its predecessor organizations, according to a March 4 news release.
Dr. Tabb has led BILH since its formation in 2019 through the merger of Beth Israel Deaconess Medical Center in Boston and Lahey Health in Burlington, Mass. He previously served as CEO of Beth Israel Deaconess beginning in 2011.
During his tenure, BILH has grown into one of New England’s largest health systems, comprising 14 hospitals and about 42,000 employees. The system provides care to approximately 1.7 million patients annually, with nearly two-thirds of that care delivered in community settings, including inpatient and outpatient sites.
“Working alongside our extraordinary community of caregivers has been one of the great privileges of my life,” Dr. Tabb said in the release, adding that the organization is well positioned to begin a search for its next leader.
Among the major initiatives during his leadership was the creation of a new partnership between Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute, both in Boston. Dana-Farber plans to end its longtime affiliation with Boston-based Brigham and Women’s Hospital in 2028 and construct a freestanding inpatient cancer hospital with Beth Israel Deaconess, a project estimated to cost $1.68 billion.
Dr. Tabb will remain in his role through 2027 during the transition, and the board expects the search for his successor to take approximately eight to 10 months.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.